Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

Enzyme calibration verifiers for creatine kinase testing

September 2024—Verichem Laboratories now offers multilevel calibration verification materials for creatine kinase activity as part of its liquid-stable, ready-to-use Enzyme ER Verifier kit. The calibration verifiers are intended to be treated as patient specimens and are available for use on a variety of wet clinical chemistry systems, including from Beckman Coulter, Abbott, Siemens Healthineers, and Roche. The kit contains 5 mL of material for each of the six levels and is stable for 18 months from the manufacturing date.

Thermo Fisher, NCI partner on myeloMATCH umbrella trial

September 2024—Thermo Fisher Scientific is partnering with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial to help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome. The study involves testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing technology so clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.

Cepheid Xpert HCV gets FDA authorization, waiver

September 2024—Cepheid has received FDA de novo marketing authorization and CLIA waiver approval for its Xpert HCV, the first point-of-care hepatitis C RNA test. The test can accurately detect active HCV infection from individuals at risk and/or with signs and symptoms of HCV infection with or without antibodies to HCV from a capillary blood sample.

Qiagen, Myriad to develop HRD test

September 2024—Qiagen and Myriad Genetics announced they will develop a globally distributable kit-based test for analyzing homologous recombination deficiency status. This next-generation sequencing test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer, and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the master collaboration agreement that the companies announced in October 2023.

Bio-Rad launches Specialty Immunoassay Plus controls

September 2024—Bio-Rad Laboratories has launched its Specialty Immunoassay Plus, a four-level, comprehensive, independent specialty immunoassay quality control designed to monitor the precision of laboratory specialty immunoassay testing procedures. The product is available in barcoded, load-and-go InteliQ and standard vial Liquichek configurations and features clinically relevant ana­lytes such as procalcitonin, interleukin-6, active vitamin B12, anti-TSH receptor, thyroid stimulating immunoglobulins, fructosamine, and others. It also contains optimized vitamin D ranges to support Vitamin D Standardization Program–compliant assays and improved intact parathyroid hormone open-vial stability to minimize QC waste. With the Unity data management software, laboratories can compare results across a large peer group of reporting labs.

Cobas Liat SARS-CoV-2, flu A/B, RSV test gets EUA

September 2024—Roche announced that the FDA has granted emergency use authorization for its Cobas Liat SARS-CoV-2, Influenza A/B, and RSV nucleic acid test for use on the Cobas Liat system. The automated multiplex real-time reverse transcription polymerase chain reaction test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus RNA in anterior nasal and nasopharyngeal swab specimens. Definitive results are generated in 20 minutes.

Siemens offers NT‑proBNPII assay on Atellica Solution

September 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure. The assay supports timely patient care with a first result available in 10 minutes. The company offers the NT-proBNPII and B-type natriuretic peptide tests on either the Atellica IM or Atellica CI analyzer.

Qiagen launches digital PCR assays for microbial applications

September 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity. The assays are available on Qiagen’s research platform GeneGlobe and are designed to target a wide range of pathogens, including dengue virus serotypes one to four, mpox clades one and two, and chikungunya, as well as malaria and various sexually transmitted infections and urinary tract infections. The addition of these assays brings the company’s total microbial dPCR assay portfolio to more than 680 targets.

MARKETPLACE

TRENDING